Image Source: Unsplash

Recursion Pharmaceuticals (RXRX) stock surged by 31.3% during the week ending June 6, 2025, driven by several key factors, namely:

• Workforce Reduction & Cost Savings: Recursion announced a 20% workforce cut to extend its cash runway to ensure sufficient liquidity through Q4 2027. This has reassured investors about the company’s long-term viability and its ability to focus on high-priority drug discovery programs.
• AI Drug Discovery Optimism: The company’s AI-driven drug discovery platform continues to attract attention, with speculation that Nvidia-backed investments could further boost its prospects.
• Analyst Ratings & Market Sentiment: Despite some price target reductions, Recursion maintained a "hold" rating from multiple analysts, with an average price target of $7.60.

About Recursion Pharmaceutical

Recursion Pharmaceuticals, Inc. engages in decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. Go here to see the company's current pipeline.

Stock Price Forecast

According to 5 professional analysts, the 12-month price target for Recursion Pharmaceuticals stock ranges from a low of $6 to a high of $10. The average analyst price target of $7.60 forecasts a 38% increase in the stock price over the next year.

Analyst Ratings

The average analyst rating for Recursion Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

More By This Author:

Quantum Computing Inc. Surged 21% W/e June 6th; After Surging 68% In May
The MunAIMarket AI-Focused Drug Discovery Stock Portfolio Has Flipped: Down 17% In May; Up 16% Last Week
Nvidia Was +24.1% In May; Continued Up 4.9% Last Week; Here's Why